Arvinas' Vepdegestrant: Why The Data May Not Hold Up
Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...
The New York Times8h
New York Times - Top Stories
These Students Ousted a Government. Now They’re Rebuilding a Democracy. It is a daunting task for Bangladesh. But an unusual mix of young people and seasoned technocrats are determined to make ...